{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T03:09:14Z","timestamp":1772766554524,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,4,15]],"date-time":"2012-04-15T00:00:00Z","timestamp":1334448000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s11060-012-0871-y","type":"journal-article","created":{"date-parts":[[2012,4,14]],"date-time":"2012-04-14T00:47:22Z","timestamp":1334364442000},"page":"23-33","source":"Crossref","is-referenced-by-count":34,"title":["Valproic acid affected the survival and invasiveness of human glioma cells through diverse mechanisms"],"prefix":"10.1007","volume":"109","author":[{"given":"Yun","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Hui","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Hong","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,4,15]]},"reference":[{"key":"871_CR1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1001\/jama.293.5.557","volume":"293","author":"SM Chang","year":"2005","unstructured":"Chang SM, Parney IF, Huang W, Anderson FA Jr, Asher AL, Bernstein M, Lillehei KO, Brem H, Berger MS, Laws ER (2005) Glioma outcomes project investigators, patterns of care for adults with newly diagnosed malignant glioma. JAMA 293:557\u2013564","journal-title":"JAMA"},{"key":"871_CR2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11060-004-2751-6","volume":"70","author":"T Demuth","year":"2004","unstructured":"Demuth T, Berens ME (2004) Molecular mechanisms of glioma cell migration and invasion. J Neurooncol 70:217\u2013228","journal-title":"J Neurooncol"},{"key":"871_CR3","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s00018-007-6342-5","volume":"64","author":"M Nakada","year":"2007","unstructured":"Nakada M, Nakada S, Demuth T, Tran NL, Hoelzinger DB, Berens ME (2007) Molecular targets of glioma invasion. Cell Mol Life Sci 64:458\u2013478","journal-title":"Cell Mol Life Sci"},{"key":"871_CR4","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2174\/138945010790711923","volume":"11","author":"J Hrebackova","year":"2010","unstructured":"Hrebackova J, Hrabeta J, Eckschlager T (2010) Valproic acid in the complex therapy of malignant tumors. Curr Drug Ther 11:361\u2013379","journal-title":"Curr Drug Ther"},{"key":"871_CR5","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/ijc.22401","volume":"120","author":"SE Furchert","year":"2007","unstructured":"Furchert SE, Lanvers-Kaminsky C, Juurgens H, Jung M, Loidl A, Fruhwald MC (2007) Inhibitors of histone deacetylase as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer 120:1787\u20131794","journal-title":"Int J Cancer"},{"key":"871_CR6","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1182\/blood-2006-03-009142","volume":"108","author":"G Garcia-Manero","year":"2006","unstructured":"Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O\u2019brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, Issa JP (2006) Phase 1\/2 study of the combination of 5-aza-2\u2032-deoxycytodine with valproic acid in patients with leukemia. Blood 108:3271\u20133279","journal-title":"Blood"},{"key":"871_CR7","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1200\/JCO.2006.08.6165","volume":"25","author":"P Munster","year":"2007","unstructured":"Munster P, Marchion D, Bicaku E, Schmitt M, Lee JH, DeConti R, Simon G, Fishman M, Minton S, Garrett C, Chiappori A, Lush R, Sullivan D, Daud A (2007) Phase 1 trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 25:1979\u20131985","journal-title":"J Clin Oncol"},{"key":"871_CR8","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1158\/0008-5472.CAN-06-2595","volume":"67","author":"Q Yang","year":"2007","unstructured":"Yang Q, Tian Y, Liu S, Zeine R, Chlenski A, Salwen HR, Henkin J, Cohn SL (2007) Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma. Cancer Res 67:1716\u20131724","journal-title":"Cancer Res"},{"key":"871_CR9","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ctrv.2007.11.003","volume":"34","author":"A Duenas-Gonzalez","year":"2008","unstructured":"Duenas-Gonzalez A, Gandelaria M, Perez-Plascencia-Cardenas E, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA (2008) Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 34:206\u2013222","journal-title":"Cancer Treat Rev"},{"key":"871_CR10","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.2174\/138161207782360528","volume":"13","author":"M Michaelis","year":"2007","unstructured":"Michaelis M, Doerr HW, Cinatl J Jr (2007) Valproic acid as anti-cancer drug. Curr Pharm Des 13:3378\u20133393","journal-title":"Curr Pharm Des"},{"key":"871_CR11","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s00415-009-5156-9","volume":"256","author":"MSM Breemen van","year":"2009","unstructured":"van Breemen MSM, Rijsman RM, Taphoorn MJB, Walchenbach R, Zwinkels H, Vecht CJ (2009) Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol 256:1519\u20131526","journal-title":"J Neurol"},{"key":"871_CR12","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s11060-008-9662-x","volume":"90","author":"JE Wolff","year":"2008","unstructured":"Wolff JE, Kramm C, Kortmann RD, Pietsch T, Rutkowski S, Jorch N, Gnekow A, Driever PH (2008) Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma. J Neurooncol 90:309\u2013314","journal-title":"J Neurooncol"},{"key":"871_CR13","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1212\/WNL.0b013e31822f02e1","volume":"77","author":"M Weller","year":"2011","unstructured":"Weller M, Gorlia T, Cairncross JG, van den Bent MJ, Mason W, Belanger K, Brandes AA, Bogdahn U, Macdonald DR, Forsyth P, Rossetti AO, Lacombe D, Mirimanoff RO, Vecht CJ, Stupp R (2011) Prolonged survival with valproic acid use in the EORTC\/NCIC temozolomide trial for glioblastoma. Neurology 77:1156\u20131164","journal-title":"Neurology"},{"key":"871_CR14","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11060-004-2338-2","volume":"72","author":"S Oberndorfer","year":"2005","unstructured":"Oberndorfer S, Piribauer M, Marosi C, Lahrmann H, Hitzenberger P, Grisold W (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in gliobasltoma patients treated with standard chemotherapy. J Neurooncol 72:255\u2013260","journal-title":"J Neurooncol"},{"key":"871_CR15","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1212\/WNL.0b013e3181bbfeca","volume":"73","author":"KA Jaeckle","year":"2009","unstructured":"Jaeckle KA, Ballman K, Furth A, Buckner JC (2009) Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma. Neurology 73:1207\u20131213","journal-title":"Neurology"},{"key":"871_CR16","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/1471-2407-10-383","volume":"10","author":"K Gotfryd","year":"2010","unstructured":"Gotfryd K, Skladchikova G, Lepekhin EA, Berezin V, Bock E, Walmod PS (2010) Cell type-specific anti-cancer properties of valproic acid: independent effects on HDAC activity and Erk1\/2 phosphorylation. BMC Cancer 10:383","journal-title":"BMC Cancer"},{"key":"871_CR17","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/sj.bjc.6602309","volume":"92","author":"MT Stockhausen","year":"2005","unstructured":"Stockhausen MT, Sjolund J, Manetopoulos C, Axelson H (2005) Effects of the histone deacetylase inhibitor valproic acid on Notch signaling in human neuroblastoma cells. Br J Cancer 92:751\u2013759","journal-title":"Br J Cancer"},{"key":"871_CR18","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0006-291X(02)02420-8","volume":"298","author":"M Ailenberg","year":"2002","unstructured":"Ailenberg M, Silverman M (2002) Trichostatin A-histone deacetylase inhibitor with clinical therapeutic potential\u2014is a selective and potent inhibitor of gelatinase A expression. Biochem Biophys Res Commun 298:110\u2013115","journal-title":"Biochem Biophys Res Commun"},{"key":"871_CR19","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.cellsig.2003.11.001","volume":"16","author":"HC Chang","year":"2004","unstructured":"Chang HC, Liu LT, Hung WC (2004) Involvement of histone deacetylation in ras-induced down-regulation of the metastasis suppressor RECK. Cell Signal 16:675\u2013679","journal-title":"Cell Signal"},{"key":"871_CR20","first-page":"3069","volume":"63","author":"LT Liu","year":"2003","unstructured":"Liu LT, Chang HC, Chiang LC, Hung WC (2003) Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res 63:3069\u20133072","journal-title":"Cancer Res"},{"key":"871_CR21","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1023\/A:1023043315031","volume":"22","author":"M Noda","year":"2003","unstructured":"Noda M, Oh J, Takahashi R, Kondo S, Kitayama H, Takahashi C (2003) RECK: a novel suppressor of malignancy linking oncogenic signaling to extracellular matrix remodeling. Cancer Metastasis Rev 22:167\u2013175","journal-title":"Cancer Metastasis Rev"},{"key":"871_CR22","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1349-7006.2006.00367.x","volume":"98","author":"HC Chang","year":"2007","unstructured":"Chang HC, Cho CY, Hung WC (2007) Downregulation of RECK by promoter methylation correlates with lymph node metastasis in non-small cell lung cancer. Cancer Sci 98:169\u2013173","journal-title":"Cancer Sci"},{"key":"871_CR23","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1053\/jhep.2001.21048","volume":"33","author":"K Furumoto","year":"2001","unstructured":"Furumoto K, Arii S, Mori A, Furuyama H, Gorrin Rivas MJ, Nakao T, Isobe N, Murata T, Takahashi C, Noda M, Imamura M (2001) RECK gene expression in hepatocellular carcinoma: correlation with invasion-related clinicopathological factors and its clinical significance. Reverse-reducing-cysteine-rich protein with Kazal motifs. Hepatology 33:189\u2013195","journal-title":"Hepatology"},{"key":"871_CR24","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/jor.20323","volume":"25","author":"HG Kang","year":"2007","unstructured":"Kang HG, Kim HS, Kim KJ, Oh JH, Lee MR, Seol SM, Han I (2007) RECK expression in osteosarcoma: correlation with matrix metalloproteinases activation and tumor invasiveness. J Orthop Res 25:696\u2013702","journal-title":"J Orthop Res"},{"key":"871_CR25","first-page":"1779","volume":"9","author":"T Masui","year":"2003","unstructured":"Masui T, Doi R, Koshiba T, Fujimoto K, Tsuji S, Nakajima S, Koizumi M, Toyoda E, Tulachan S, Ito D, Kami K, Mori T, Wada M, Noda M, Imamura M (2003) RECK expression in pancreatic cancer: its correlation with lower invasiveness and better prognosis. Clin Cancer Res 9:1779\u20131784","journal-title":"Clin Cancer Res"},{"key":"871_CR26","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.eururo.2006.05.050","volume":"51","author":"A Rabien","year":"2007","unstructured":"Rabien A, Burkhardt M, Jung M, Fritzsche F, Ringsdorf M, Schicktanz H, Loening SA, Kristiansen G, Jung K (2007) Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy. Eur Urol 51:1259\u20131266","journal-title":"Eur Urol"},{"key":"871_CR27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejca.2005.09.016","volume":"42","author":"SY Song","year":"2006","unstructured":"Song SY, Son HJ, Nam E, Rhee JC, Park C (2006) Expression of reversion-inducing-cysteine-rich protein with Kazal motifs as a prognostic indicator in gastric cancer. Eur J Cancer 42:101\u2013108","journal-title":"Eur J Cancer"},{"key":"871_CR28","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1002\/cncr.11395","volume":"97","author":"PN Span","year":"2003","unstructured":"Span PN, Sweep CG, Manders P, Beex LV, Leppert D, Lindberg RL (2003) Matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs: a prognostic marker for good clinical outcome in human breast carcinoma. Cancer 97:2710\u20132715","journal-title":"Cancer"},{"key":"871_CR29","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.canlet.2005.06.009","volume":"237","author":"MF Jagt Van der","year":"2006","unstructured":"Van der Jagt MF, Sweep FC, Waas ET, Hendriks T, Ruers TJ, Merry AH, Wobbes T, Span PN (2006) Correlation of reversion-inducing cysteine-rich protein with kazal motifs (RECK) and extracellular matrix metalloproteinase inducer (EMMPRIN), with MMP-2, MMP-9, and survival in colorectal cancer. Cancer Lett 237:289\u2013297","journal-title":"Cancer Lett"},{"key":"871_CR30","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0361-090X(02)00123-X","volume":"26","author":"RM Sasahara","year":"2002","unstructured":"Sasahara RM, Brochado SM, Takahashi C, Oh J, Maria-Engler SS, Granjeiro JM, Noda M, Sogayar MC (2002) Transcriptional control of the RECK metastasis\/angiogenesis suppressor gene. Cancer Detect Prev 26:435\u2013443","journal-title":"Cancer Detect Prev"},{"key":"871_CR31","doi-asserted-by":"crossref","first-page":"128","DOI":"10.5483\/BMBRep.2003.36.1.128","volume":"36","author":"SO Yoon","year":"2003","unstructured":"Yoon SO, Park SJ, Yun CH, Chung AS (2003) Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol 36:128\u2013137","journal-title":"J Biochem Mol Biol"},{"key":"871_CR32","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/jcb.22472","volume":"110","author":"TC Silveira Correa","year":"2010","unstructured":"Silveira Correa TC, Massaro RR, Brohem CA, Taboga SR, Lamers ML, Santos MF, Maria-Engler SS (2010) RECK-mediated inhibition of glioma migration and invasion. J Cell Biochem 110:52\u201361","journal-title":"J Cell Biochem"},{"key":"871_CR33","doi-asserted-by":"crossref","first-page":"5369","DOI":"10.1128\/MCB.00479-08","volume":"28","author":"G Gabriely","year":"2008","unstructured":"Gabriely G, Wurdinger T, Kesari S, Esau CC, Burchard J, Linsley PS, Krichevsky AM (2008) MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol 28:5369\u20135380","journal-title":"Mol Cell Biol"},{"key":"871_CR34","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/jcb.20923","volume":"99","author":"TC Silveira Correa","year":"2006","unstructured":"Silveira Correa TC, Brohem CA, Winnischofer SM, da Silva Cardeal LB, Sasahara RM, Taboga SR, Sogayar MC, Maria-Engler SS (2006) Downregulation of the RECK-tumor and metastasis suppressor gene in glioma invasiveness. J Cell Biochem 99:256\u2013267","journal-title":"J Cell Biochem"},{"key":"871_CR35","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1038\/sj.onc.1210414","volume":"26","author":"S Meloche","year":"2007","unstructured":"Meloche S, Pouyssegur J (2007) The ERK1\/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 26:3227\u20133239","journal-title":"Oncogene"},{"key":"871_CR36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/02699050500284218","volume":"24","author":"S Yoon","year":"2006","unstructured":"Yoon S, Seger R (2006) The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 24:21\u201344","journal-title":"Growth Factors"},{"key":"871_CR37","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1007\/s00018-008-8170-7","volume":"65","author":"M Krishna","year":"2008","unstructured":"Krishna M, Narang H (2008) The complexity of mitogen-activated protein kinases (MAPKs) made simple. Cell Mol Life Sci 65:3525\u20133544","journal-title":"Cell Mol Life Sci"},{"key":"871_CR38","first-page":"119","volume":"29","author":"VM Zohrabian","year":"2009","unstructured":"Zohrabian VM, Forzani B, Chau Z, Murali R, Jhanwar-Uniyal M (2009) Rho\/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation. Anticancer Res 29:119\u2013124","journal-title":"Anticancer Res"},{"key":"871_CR39","doi-asserted-by":"crossref","first-page":"21888","DOI":"10.1074\/jbc.M313694200","volume":"279","author":"B Annabi","year":"2004","unstructured":"Annabi B, Thibeault S, Moumdjian R, B\u00e9liveau R (2004) Hyaluronan cell surface binding is induced by type I collagen and regulated by caveolae in glioma cells. J Biol Chem 279:21888\u201321896","journal-title":"J Biol Chem"},{"key":"871_CR40","doi-asserted-by":"crossref","first-page":"31674","DOI":"10.1074\/jbc.M104309200","volume":"276","author":"PX Yuan","year":"2001","unstructured":"Yuan PX, Huang LD, Jiang YM, Gutkind JS, Manji HK, Chen G (2001) The mood stabilizer valproic acid activates mitogen-activated protein kinases and promote neurite growth. J Biol Chem 276:31674\u201331683","journal-title":"J Biol Chem"},{"key":"871_CR41","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00277-011-1175-6","volume":"90","author":"AH Wang","year":"2011","unstructured":"Wang AH, Wei L, Chen L, Zhao SQ, Wu WL, Shen ZX, Li JM (2011) Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells. Ann Hematol 90:917\u2013931","journal-title":"Ann Hematol"},{"key":"871_CR42","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11060-011-0725-z","volume":"107","author":"KA Nifterik Van","year":"2012","unstructured":"Van Nifterik KA, Van den Berg J, Slotman BJ, Lafleur MV, Sminia P, Stalpers LJ (2012) Valproic acid sensitizes human glioma cells for temozolomide and \u03b3-radiation. J Neurooncol 107:61\u201367","journal-title":"J Neurooncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-012-0871-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-012-0871-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-012-0871-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T06:13:02Z","timestamp":1713852782000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-012-0871-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,15]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["871"],"URL":"https:\/\/doi.org\/10.1007\/s11060-012-0871-y","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,15]]}}}